Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jul 12:2018:2895958.
doi: 10.1155/2018/2895958. eCollection 2018.

Exploring Long Noncoding RNAs in Glioblastoma: Regulatory Mechanisms and Clinical Potentials

Affiliations
Review

Exploring Long Noncoding RNAs in Glioblastoma: Regulatory Mechanisms and Clinical Potentials

Tao Zeng et al. Int J Genomics. .

Abstract

Gliomas are primary brain tumors presumably derived from glial cells. The WHO grade IV glioblastoma (GBM), characterized by rapid cell proliferation, easily recrudescent, high morbidity, and mortality, is the most common, devastating, and lethal gliomas. Molecular mechanisms underlying the pathogenesis and progression of GBMs with potential diagnostic and therapeutic value have been explored industriously. With the advent of high-throughput technologies, numerous long noncoding RNAs (lncRNAs) aberrantly expressed in GBMs were discovered recently, some of them probably involved in GBM initiation, malignant progression, relapse and resistant to therapy, or showing diagnostic and prognostic value. In this review, we summarized the profile of lncRNAs that has been extensively investigated in glioma research, with a focus on their regulatory mechanisms. Then, their diagnostic, prognostic, and therapeutic implications were also discussed.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Stupp R., Mason W. P., van den Bent M. J., et al. Radiotherapy plus concomitant and adjuvant Temozolomide for glioblastoma. The New England Journal of Medicine. 2005;352(10):987–996. doi: 10.1056/NEJMoa043330. - DOI - PubMed
    1. Stupp R., Taillibert S., Kanner A., et al. Effect of tumor-treating fields plus maintenance Temozolomide vs maintenance Temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318(23):2306–2316. doi: 10.1001/jama.2017.18718. - DOI - PMC - PubMed
    1. Ostrom Q. T., Bauchet L., Davis F. G., et al. The epidemiology of glioma in adults: a “state of the science” review. Neuro-Oncology. 2014;16(7):896–913. doi: 10.1093/neuonc/nou087. - DOI - PMC - PubMed
    1. Stupp R., Hegi M. E., Gilbert M. R., Chakravarti A. Chemoradiotherapy in malignant glioma: standard of care and future directions. Journal of Clinical Oncology. 2007;25(26):4127–4136. doi: 10.1200/JCO.2007.11.8554. - DOI - PubMed
    1. Delgado-Lopez P. D., Corrales-Garcia E. M. Survival in glioblastoma: a review on the impact of treatment modalities. Clinical and Translational Oncology. 2016;18(11):1062–1071. doi: 10.1007/s12094-016-1497-x. - DOI - PubMed

LinkOut - more resources